Gallium 68–labeled fibroblast-activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucose PET/CT for the staging of biliary tract cancer. Background Gallium 68–labeled fibroblast-activation protein inhibitor (68Ga-FAPI), an imaging agent for detecting tumors, represents a promising alternative to fluorine 18 fluorodeoxyglucose (18F-F...

A 50-year-old woman presented with back pain for 1 month. Chest CT showed osteolytic destruction of T6 vertebral body. A malignancy was suspected. The patient was subsequently enrolled in the clinical trial of ⁶⁸Ga-FAPI PET/CT. ⁶⁸Ga-FAPI PET/CT revealed multiple bone destruction with increased FAPI activity. It was also highly suggestive of malignancy or metastases. However, pathological examination after T6 vertebral surgery confirmed the diagnosis of tuberculous granulomatous inflammation.

Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone tumor associated with risks of sarcoma and metastasis. Once malignancy occurs, the prognosis is generally poor. Surgery remains the main treatment for GCTB. Multidisciplinary management is a feasible option for patients wherein surgical resection is not an option or for those with serious surgery-related complications. Denosumab is an anti-nuclear factor kappa B ligand approved for the treatment of postmenopausal women with osteoporosis, bone metastases, and advanced or inoperable GCTB. However, the guidelines for treating GCTB are unclear; its short-term efficacy and safety in inoperable patients have been demonstrated. Lengthier therapies (high cumulative doses) or pre-operative adjuvant therapy may be associated with severe complications and high local recurrence rates. Short-term administration helps attain satisfactory local control and functionality. As a result, lately, the impact of different doses and lengths of treatment on the efficacy of denosumab in GCTB treatment, the incidence of complications, and recurrence rates have gained attention. The efficacy and safety of denosumab against GCTB, its impact on imaging assessment, related complications, and recurrence of GCTB were previously reviewed. For further research direction, this paper reviews the progress of studies evaluating the impact of the dose and duration of denosumab therapy for GCTB.

A 69-year-old man presented with dysphagia for 6 months. Endoscopic biopsy showed no sign of malignancy, but enhanced chest CT revealed thickening of the esophageal wall, which was considered likely a potential malignancy. The patient subsequently was enrolled in our clinical trial of ⁶⁸Ga-FAPI study in tumors. Intense ⁶⁸Ga-FAPI activity was noted in the thickened esophagus. However, repeated endoscopic biopsies and relief of symptoms after drug treatment rendered a diagnosis of Candida albicans esophagitis.

A 69-year-old man presented with newly diagnosed esophageal cancer was enrolled in our clinical trial of ⁶⁸Ga-FAPI PET/CT study in tumors. Increased tracer uptake was noted in esophageal cancer. In addition, the facet joint osteoarthritis of T7/8 vertebrae also revealed elevated ⁶⁸Ga-FAPI uptake.

A 40-year-old man presented with abdominal pain and diarrhea for 2 months. Abdominal CT showed thickening of the cecal wall, which was considered likely malignant. The patient was subsequently enrolled in a clinical trial of ⁶⁸Ga-FAPI PET/CT study in tumors. Intense ⁶⁸Ga-FAPI activity was noted in the thickened cecum, also suggestive of malignancy. However, pathological examination from biopsy rendered a diagnosis of chronic colitis.